First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia

被引：6

作者：

Argyropoulos, Kimon V. ^{[1
]}

Lia, M. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Program Immunol, 408 East 69th St, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10065 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期

关键词：

Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors; B-CELL-RECEPTOR; ATRIAL-FIBRILLATION; GENE REARRANGEMENT; SOMATIC MUTATION; CLINICAL-TRIAL; IBRUTINIB USE; ACTIVATION; BTK; RESISTANCE; MYD88;

D O I：

10.1016/j.hoc.2018.05.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.

引用

下载

页码：853 / +

页数：13

共 50 条

[31] Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
Thompson, Philip A.
Burger, Jan A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 31 - 42
[32] Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk
Erblich, Thomas
Manisty, Charlotte
Gribben, John
CASE REPORTS IN HEMATOLOGY, 2024, 2024
[33] Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
Smith, T. Alexander
Verma, Sumit
Liu, Yi
Sikirica, Slaven
Janjan, Nora Anita
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] CLINICAL CONSEQUENCES AND ASSOCIATED COSTS OF TREATING PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA IN THE FIRST-LINE SETTING WITH BRUTON TYROSINE KINASE INHIBITORS
Crawford, S.
Li, H.
Salkar, M.
Yu, X.
Martin, P.
VALUE IN HEALTH, 2024, 27 (06) : S150 - S150
[35] Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
Ke, Liyuan
Li, Su
Huang, Danxue
Wang, Yan
FRONTIERS IN PHARMACOLOGY, 2024, 15
[36] First-generation versus second-generation antipsychotic drugs for depression in schizophrenia
Corbo, M.
Acciavatti, T.
Marini, S.
Cinosi, E.
Di Tizio, L.
Di Caprio, L.
Viceconte, D.
Matteo, L.
Giuseppe, D. I.
Martinotti, G.
Di Giannantonio, M.
EUROPEAN PSYCHIATRY, 2016, 33 : S245 - S245
[37] Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia
Munakata, Wataru
Sekiguchi, Naohiro
Shinya, Rai
Suzuki, Kenshi
Handa, Hiroshi
Shibayama, Hirohiko
Endo, Tomoyuki
Terui, Yasuhito
Iwaki, Noriko
Fukuhara, Noriko
Tatetsu, Hiro
Iida, Shinsuke
Ishikawa, Takayuki
Shiibashi, Ryota
Izutsu, Koji
BLOOD, 2019, 134
[38] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
Elisabetta Abruzzese
Massimo Breccia
Roberto Latagliata
BioDrugs, 2014, 28 : 17 - 26
[39] Bruton Tyrosine Kinase Inhibitors Next Generation: The Development continues
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (12) : 765 - 765
[40] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
Abruzzese, Elisabetta
Breccia, Massimo
Latagliata, Roberto
BIODRUGS, 2014, 28 (01) : 17 - 26

← 1 2 3 4 5 →